Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.

Du F, Hinke SA, Cavanaugh C, Polidori D, Wallace N, Kirchner T, Jennis M, Lang W, Kuo GH, Gaul MD, Lenhard J, Demarest K, Ajami NJ, Liang Y, Hornby PJ.

J Pharmacol Exp Ther. 2018 Jun;365(3):676-687. doi: 10.1124/jpet.118.248575. Epub 2018 Apr 19.

PMID:
29674332
2.

Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody.

Hinke SA, Cieniewicz AM, Kirchner T, D'Aquino K, Nanjunda R, Aligo J, Perkinson R, Cooper P, Boayke K, Chiu ML, Jarantow S, Lacy ER, Liang Y, Johnson DL, Whaley JM, Lingham RB, Kihm AJ.

Mol Metab. 2018 Apr;10:87-99. doi: 10.1016/j.molmet.2018.01.014. Epub 2018 Feb 3.

3.

State-Dependent Allosteric Inhibition of the Human SLC13A5 Citrate Transporter by Hydroxysuccinic Acids, PF-06649298 and PF-06761281.

Rives ML, Shaw M, Zhu B, Hinke SA, Wickenden AD.

Mol Pharmacol. 2016 Dec;90(6):766-774. Epub 2016 Oct 17.

PMID:
27754898
4.

Novel Monoclonal Antibody Is an Allosteric Insulin Receptor Antagonist That Induces Insulin Resistance.

Cieniewicz AM, Kirchner T, Hinke SA, Nanjunda R, D'Aquino K, Boayke K, Cooper PR, Perkinson R, Chiu ML, Jarantow S, Johnson DL, Whaley JM, Lacy ER, Lingham RB, Liang Y, Kihm AJ.

Diabetes. 2017 Jan;66(1):206-217. doi: 10.2337/db16-0633. Epub 2016 Oct 26.

5.

AKAP150 participates in calcineurin/NFAT activation during the down-regulation of voltage-gated K(+) currents in ventricular myocytes following myocardial infarction.

Nieves-Cintrón M, Hirenallur-Shanthappa D, Nygren PJ, Hinke SA, Dell'Acqua ML, Langeberg LK, Navedo M, Santana LF, Scott JD.

Cell Signal. 2016 Jul;28(7):733-40. doi: 10.1016/j.cellsig.2015.12.015. Epub 2015 Dec 24.

6.

AKAP150 contributes to enhanced vascular tone by facilitating large-conductance Ca2+-activated K+ channel remodeling in hyperglycemia and diabetes mellitus.

Nystoriak MA, Nieves-Cintrón M, Nygren PJ, Hinke SA, Nichols CB, Chen CY, Puglisi JL, Izu LT, Bers DM, Dell'acqua ML, Scott JD, Santana LF, Navedo MF.

Circ Res. 2014 Feb 14;114(4):607-15. doi: 10.1161/CIRCRESAHA.114.302168. Epub 2013 Dec 9.

7.

Anchored phosphatases modulate glucose homeostasis.

Hinke SA, Navedo MF, Ulman A, Whiting JL, Nygren PJ, Tian G, Jimenez-Caliani AJ, Langeberg LK, Cirulli V, Tengholm A, Dell'Acqua ML, Santana LF, Scott JD.

EMBO J. 2012 Oct 17;31(20):3991-4004. doi: 10.1038/emboj.2012.244. Epub 2012 Aug 31. Erratum in: EMBO J. 2012 Nov 28;31(23):4481.

8.

Epac2: a molecular target for sulfonylurea-induced insulin release.

Hinke SA.

Sci Signal. 2009 Aug 25;2(85):pe54. doi: 10.1126/scisignal.285pe54.

PMID:
19706871
9.

Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes.

Hinke SA.

Curr Opin Mol Ther. 2008 Oct;10(5):516-25. Review.

PMID:
18830927
10.

Finding GAD: early detection of beta-cell injury.

Hinke SA.

Endocrinology. 2007 Oct;148(10):4568-71. Review. No abstract available.

PMID:
17876036
11.

MyRIP anchors protein kinase A to the exocyst complex.

Goehring AS, Pedroja BS, Hinke SA, Langeberg LK, Scott JD.

J Biol Chem. 2007 Nov 9;282(45):33155-67. Epub 2007 Sep 7.

12.

Methyl succinate antagonises biguanide-induced AMPK-activation and death of pancreatic beta-cells through restoration of mitochondrial electron transfer.

Hinke SA, Martens GA, Cai Y, Finsi J, Heimberg H, Pipeleers D, Van de Casteele M.

Br J Pharmacol. 2007 Apr;150(8):1031-43. Epub 2007 Mar 5.

13.

Increased oxygen radical formation and mitochondrial dysfunction mediate beta cell apoptosis under conditions of AMP-activated protein kinase stimulation.

Cai Y, Martens GA, Hinke SA, Heimberg H, Pipeleers D, Van de Casteele M.

Free Radic Biol Med. 2007 Jan 1;42(1):64-78. Epub 2006 Sep 27.

PMID:
17157194
14.

Relative contribution of incretins to the glucose lowering effect of DP IV inhibitors in type 2 diabetes mellitus (T2DM).

Hinke SA, Pederson RA, McIntosh CH.

Adv Exp Med Biol. 2006;575:119-33. Review. No abstract available.

PMID:
16700515
15.

In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide.

Hinke SA, Manhart S, Speck M, Pederson RA, Demuth HU, McIntosh CH.

Life Sci. 2004 Aug 27;75(15):1857-70.

PMID:
15302229
16.

Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness.

Delmeire D, Flamez D, Moens K, Hinke SA, Van Schravendijk C, Pipeleers D, Schuit F.

Biochem Pharmacol. 2004 Jul 1;68(1):33-9.

PMID:
15183115
17.

Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal.

Hinke SA, Hellemans K, Schuit FC.

J Physiol. 2004 Jul 15;558(Pt 2):369-80. Epub 2004 Jun 4. Review.

18.

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.

Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ.

Diabetes. 2004 May;53(5):1326-35.

19.

[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.

Hinke SA, Manhart S, Kühn-Wache K, Nian C, Demuth HU, Pederson RA, McIntosh CH.

J Biol Chem. 2004 Feb 6;279(6):3998-4006. Epub 2003 Nov 10.

20.

Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1.

Delmeire D, Flamez D, Hinke SA, Cali JJ, Pipeleers D, Schuit F.

Diabetologia. 2003 Oct;46(10):1383-93. Epub 2003 Sep 17.

PMID:
13680124
21.

Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP).

Hinke SA, Gelling R, Manhart S, Lynn F, Pederson RA, Kühn-Wache K, Rosche F, Demuth HU, Coy D, McIntosh CH.

Biol Chem. 2003 Mar;384(3):403-7.

PMID:
12715891
22.

Glucose-dependent insulinotropic polypeptide (GIP): development of DP IV-resistant analogues with therapeutic potential.

Hinke SA, Lynn F, Ehses J, Pamir N, Manhart S, Kühn-Wache K, Rosche F, Demuth HU, Pederson RA, McIntosh CH.

Adv Exp Med Biol. 2003;524:293-301. No abstract available.

PMID:
12675251
23.

Structure-function analysis of a series of novel GIP analogues containing different helical length linkers.

Manhart S, Hinke SA, McIntosh CH, Pederson RA, Demuth HU.

Biochemistry. 2003 Mar 18;42(10):3081-8.

PMID:
12627975
24.

Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.

Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, Miyawaki K, Yamada Y, Seino Y, McIntosh CH, Pederson RA.

Am J Physiol Endocrinol Metab. 2003 May;284(5):E931-9. Epub 2003 Jan 21.

25.

A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells.

Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N, McIntosh CH, Pederson RA.

FASEB J. 2003 Jan;17(1):91-3. Epub 2002 Nov 15.

PMID:
12475913
27.

On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.

Hinke SA, McIntosh CH, Hoffmann T, Kühn-Wache K, Wagner L, Bär J, Manhart S, Wermann M, Pederson RA, Demuth HU.

Diabetes Care. 2002 Aug;25(8):1490-1; author reply 1491-2. No abstract available.

PMID:
12145269
28.

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU.

Biochem Biophys Res Commun. 2002 Mar 15;291(5):1302-8.

PMID:
11883961
29.

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats.

Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU, McIntosh CH.

Diabetes. 2002 Mar;51(3):652-61.

30.

Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP).

Hinke SA, Manhart S, Pamir N, Demuth H, W Gelling R, Pederson RA, McIntosh CH.

Biochim Biophys Acta. 2001 May 5;1547(1):143-55.

PMID:
11343800
31.

Metabolism of glucagon by dipeptidyl peptidase IV (CD26).

Pospisilik JA, Hinke SA, Pederson RA, Hoffmann T, Rosche F, Schlenzig D, Glund K, Heiser U, McIntosh CH, Demuth H.

Regul Pept. 2001 Jan 12;96(3):133-41.

PMID:
11111019
32.

Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance.

Kühn-Wache K, Manhart S, Hoffmann T, Hinke SA, Gelling R, Pederson RA, McIntosh CH, Demuth HU.

Adv Exp Med Biol. 2000;477:187-95. No abstract available.

PMID:
10849746
33.

Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide.

Hinke SA, Pauly RP, Ehses J, Kerridge P, Demuth HU, McIntosh CH, Pederson RA.

J Endocrinol. 2000 May;165(2):281-91.

PMID:
10810292
34.

Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs.

Hinke SA, Pospisilik JA, Demuth HU, Mannhart S, Kühn-Wache K, Hoffmann T, Nishimura E, Pederson RA, McIntosh CH.

J Biol Chem. 2000 Feb 11;275(6):3827-34.

35.
36.

Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin.

McIntosh CH, Bremsak I, Lynn FC, Gill R, Hinke SA, Gelling R, Nian C, McKnight G, Jaspers S, Pederson RA.

Endocrinology. 1999 Jan;140(1):398-404.

PMID:
9886851

Supplemental Content

Loading ...
Support Center